Bretylium

Summary

Bretylium (CHEMBL1199080) is an approved small-molecule adrenergic antagonist.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 243.16 Da · C11H17BrN+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1199080
Name	Bretylium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2431
ChEBI	CHEBI:3172
Molecular formula	C11H17BrN+
Molecular weight	243.16
InChIKey	AAQOQKQBGPPFNS-UHFFFAOYSA-N

SMILES: CC[N+](C)(C)CC1=CC=CC=C1Br

IUPAC name: (2-bromophenyl)methyl-ethyl-dimethylazanium

ChEBI definition: A quaternary ammonium cation having 2-bromobenzyl, ethyl and two methyl groups attached to the nitrogen. It blocks noradrenaline release from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation.

Pharmacological roles (ChEBI): adrenergic antagonist, anti-arrhythmia drug, antihypertensive agent.

Also known as: Bretylium cation, Bretylium ion, Bretylium, SID50113154, SID50113155, bretylium, BRETYLIUM TOSILATE, BRETYLIUM

Parent form; salt/anhydrous children: CHEMBL1095292

Patent coverage: 1,064 distinct patent families (3,766 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,765 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).